skip to the content

Clinical Trials

Cancer - Bone Density Study

GOG 0215: A Phase II Randomized Study of the effect of Zoledronic Acid versus Observation on bone mineral density of the lumbar spine in women who elect to undergo surgery that results in removal of both ovaries

Protocol ID

08-123

Protocol Description

The purpose of this study is to look at the effects of zoledronic acid (Zometa) on preventing bone loss in women who undergo early menopause due to surgical removal of their ovaries. While Zometa is approved by the Food and Drug Administration (FDA) for treating osteoporosis in post-menopausal women, it is not currently approved for treatment of women who undergo early menopause as a result of surgical removal of the ovaries. Its use in this study is considered experimental.

Eligibility Criteria

Women who have or will undergo surgery to remove their ovaries

Primary Investigator(s)

  • Veena John, MD

Contact Information

Laureen Thumser, RN
(516) 734-8979
lthumser@nshs.edu

Last Update

March 29, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
top
top